GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures

Plug Pulled After Three Trial Flops

 
• By Andrew McConaghie

Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.

GSK Exit
GSK is exiting the deal after paying an upfront fee of $360m, but will not have to pay any milestones after bintrafusp's disappointing results.

More from Business

More from Scrip